Replies to post #3346 on Halozyme Therapeutics Inc (HALO)

[friendofthedevil]

Fritz,

I believe RAWNOC's reference is only to HyQvia and Halo's PH20. I think it is a cool, if tangential, find and perhaps gives a little boost to the idea HyQvia will find an eager market. Of course, the rate limiting step will be Baxter's ability to produce or find enough IgG to expand that market. But it is nice to know a company that sells a SC infusion device thinks HyQvia is enough of a game changer to mention it in their 10-Q filing.

fotd